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Abstract
Background: Malaria is an important public health problem in Africa. Pregnant women are a vulnerable
population and this disease can underlie an increased risk of low-birth weight newborns (< 2500 g); these women
therefore need management during pregnancy. This was previously provided by chloroquine treatment, which,
because of compliance problems and drug resistance, was replaced by intermittent preventive treatment with
sulfadoxine-pyrimethamine (ITPp-SP) with two single doses taken after 16 weeks of amenorrhea, at least 4 weeks
apart. This protocol was recommended by the World Health Organization (WHO) in 1998 and was initiated in
Benin in 2006 after its political adoption in 2004.
A retrospective longitudinal study was conducted in eight maternity hospitals in two geographical areas in Benin
(in the south and north). The study investigated 2420 women who gave birth from 2005 to 2009. The antenatal
cards of those women were randomly selected over 5 years with the aim of analyzing the IPT coverage in the
study’s maternity hospitals.
Results: The rate of IPT-SP coverage evolved from 3.7% in 2005 to 87.8% in 2009 for women who had received at
least one dose and from 2.7% to 68.4% from 2005 to 2009 for those who had received complete ITP (two doses).
Variability in the results was observed depending on the geographical area (north/south) and the type of area
(rural/urban).
Conclusions: In total, application of IPT-SP 2-doses has rapidly evolved since 2005, but the objective of 80% IPT
coverage has not yet been achieved throughout the country. Moreover, problems of drug shortage recurring in
the field (reported by health staff) remain to be resolved.
Background
Malaria is an important world public health problem,
particularly in Africa [1]. In Benin, in 2008, malaria was
the leading cause for medical consultation (39.6% of dis-
orders encountered in consultation), hospitalization
(20.1% of the causes of hospitalization), and death
(15.7% of the causes of death) [2]. High-risk populations
are children under 5 years of age and pregnant women
in areas where malaria transmission is high [3]. Malarial
infections during pregnancy are reported to cause the
death of 200,000 infants every year [4] and 30 million
pregnant women are estimated to live in endemic areas
[5]. In high-transmission areas, the main consequences
of gestational malaria are anemia in the pregnant
woman and low birth weight in the newborn, which is
associated with an increased risk of morbidity and mor-
tality in the first years of life [6].
Aiming to reduce the consequences of gestational
malaria, the World Health Organization (WHO) recom-
mends a series of interventions [6-8] including Intermit-
tent Preventive Treatment (IPT) with Sulfadoxine-
Pyrimethamine (SP) in high malaria transmission areas.
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of chloroquine resistance [9-11] and the observation of
poor compliance on the part of pregnant women [9,10].
ITPp consists of administering, to all pregnant women,
two curative doses of an effective antimalarial drug as a
preventive measure during regular prenatal consulta-
tions [6,7]. SP is administered orally in a single dose
supervised beginning the 16
th week of amenorrhea. Sev-
eral randomized clinical trials on the intermittent treat-
ment of gestational malaria with sulfadoxine-
pyrimethamine have been conducted in Africa [12-17]
and SP has been shown to be the most effective medica-
tion for pregnant women in preventing gestational
malaria [7]. This policy has been adopted by many Afri-
can countries and was adopted in Benin in 2004, but its
implementation in the field did not truly begin until
2006. A study conducted in Benin from 2004 to 2005
[18] proved the efficacy of ITP-SP compared with
chloroquine.
Since the implementation of ITPp-SP treatment in
Benin, several studies have evaluated the degree of ITPp
coverage (the Health Demographic Study conducted in
2006 and a study sponsored by the National Malaria
Control Program ([Programme National de Lutte contre
le Paludisme: PNLP] in 2007) [19]. It therefore seems
important to assess the ITP situation since this last
study. The main objective of the present study was
therefore to estimate the changes in ITPp-SP coverage
s i n c e2 0 0 5u pt o2 0 0 9i nt h ec o u n t r y ’st w oz o n e s( o n e
in the north and one in the south).
Methods
Context
The study was conducted in four towns in Benin, two in
the south and two in the north, with one rural town
a n do n eu r b a nt o w ni ne a c ha r e a :T o r iB o s s i t oa n d
Cotonou in the south and Malanville and Karimama in
the north (Figure 1). The study was conducted in two
maternity hospitals in each town for a total of four in
the south and four in the north, with four located in
rural areas (Tori Cada and Tori Avamè maternity hospi-
tals in the south, Guéné and Birni Lafia maternity hospi-
tals in the north) and four located in urban areas (the
CNHU and Zogbo maternity hospitals in Cotonou in
the south, and the Hôpital de Zone of Malanville and
Malanville Health Center in the north). The choice of
these study sites (not representative sample of all of
Benin) was based on budget and ease of access
considerations.
Situated in an intertropical zone, Benin has a hot and
humid climate. In the south, two rainy seasons are
observed (from April to July, then from October to
November). In the north, the year is divided into a rainy
season (May to October) and a dry season (November
to April).
Transmission of malaria in Benin is perennial and
malaria is rife throughout the year, with periods of
recrudescence during the rainy seasons [20]. Anopheles
gambiae s. s. has been identified ast h em a i nv e c t o ro f
disease transmission and Plasmodium falciparum as the
most frequently encountered parasite (97.1%); the spe-
cies Anopheles funestus is also present [21,22].
Method
This was a retrospective longitudinal study consisting of
collecting data from maternity registries relative to the
progression of pregnancy in women who were pregnant
during the 5 years between 1 January 2005 and 31
December 2009. The year 2005, before the study began,
is the reference for analysis of the evolution of the IPT
coverage rate.
Karimama
Cotonou
Malanville
Tori 
Bossito
Figure 1 Map of Benin.
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about difficulties encountered in IPTp implementation.
Sampling
A sample of 2420 pregnant women was constituted as
follows: in each maternity hospital, a minimum of 60
maternal cards were chosen per year as the sample
covering all the months of the study year, i.e., at least
300 cards for the entire duration of the study for each
maternity hospital. All the year’s cards were divided
over the 12 months and a random selection was made
for each month, i.e., five cards per month. The cards
of women who did not give birth at the maternity
hospital or those whose pregnancy was not monitored
at the hospital were excluded from the random
selection.
Statistical analyses
The ITP coverage rate was studied and defined in two
ways:
- the proportion of women who had received at least
one ITP dose during their pregnancy, designated as
“ITP coverage-at least one dose";
- the proportion who had received both ITP doses
recommended, designated as “ITP coverage-two
doses.”
After a descriptive study (comparison of the progres-
sion of coverage between the maternity hospitals), the
analysis consisted in logistic regression modeling of the
probability of a women receiving either at least one dose
of ITP or two doses of ITP in relation to certain factors
(explanatory variables):
- the geographical area (north, south),
- the type of town (urban or rural),
- the study period (2005, 2006-2007, 2008-2009),
- the number of consultations (< four prenatal con-
sultations, ≥ four prenatal consultations),
- parity (primipara, secundipara, multipara),
- gestational complications (with or without
complications),
- season (dry, rainy),
-t h ew o m a n ’s age (< 18 years, 18-34 years, ≥ 35
years).
A univariate analysis was performed between the vari-
able to explain the above-mentioned cofactors, then the
significant covariates were selected to construct the final
model obtained after multivariate analysis.
All the analyses were performed using STATA Ver-
sion 11.
Ethics
IRD ethical committee and the National Research Ethi-
cal Committee of Benin gave their clearance for the
study (Comité National Provisoire d’Ethique pour la
Recherche en Santé, reference number IRB00006860).
Results
Study population characteristics
The mean age of the women was 26 years (standard
deviation [SD] = 5), the minimum age was 12 years, and
the oldest woman was 45 years old.
The primiparae accounted for 19.4% of the women in
the study. The average parity was four pregnancies (SD
= 2), varying from 1 to 13.
The mean number of prenatal consultations was four
(SD = 2), varying from 1 to 13 consultations, with 72.1%
of the women having attended at least four
consultations.
The first prenatal consultation occurred at a mean 16
weeks (SD = 8) of amenorrhea (median = 14 weeks).
The first consultation took place during the first trime-
ster of pregnancy (i.e., before the 16
th week of amenor-
rhea) for 56.0% of the women.
Overall ITP-SP coverage in pregnant women from 2005 to
2009
Figure 2 represents the changes in ITP-SP from 2005 up
to 2009, in all the study’s maternity hospitals. It shows
that ITP started very slowly in 2005. The ITP coverage
rate showed a rapid increase after 2006, then a less
rapid increase after 2008. From 2006 to 2009, a constant
gap between the progression of the coverage rate of
“ITP-at least one dose” and the rate of “ITP-two doses”
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Figure 2 Overall progression of ITP intake in pregnant women
from 2005 to 2009 in the study’s maternity hospital.
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Page 3 of 7can be observed. In 2009, again 15% of the pregnant
women registered in consultation did not receive a sin-
gle dose of ITP and 30% did not receive the two doses
required.
ITP coverage rate per maternity hospital
from 2005 to 2009
In 2005, as indicated in Figure 3, the level of “ITP-at
least one dose” (ITPp 1) use was low in all the mater-
nity hospitals (< 10%). During the 2006-2007 period,
t h er a t eo f“ITP-at least one dose” coverage varied
between 33.9% (CNHU) and 92.6% (Guéné). During
the 2008-2009 period, the rate of “ITP-at least one
dose” coverage improved and varied between 61.3%
(CNHU) and 95.3% (Avamè). In all cases, good pro-
gression was observed over time, bringing to light two
groups. Some maternity hospitals experienced a rapid
start, above 60% “ITP-at least one dose” coverage dur-
ing 2006-2007 and then evolved less quickly: the
maternity hospitals in the north and Avamè. The
others, located in the south, evolved more slowly, in a
linear fashion and in relation to time: the CNHU,
Zogbo, and Tori Cada maternity hospitals.
Figure 4 shows the progression of the “ITP-two doses”
coverage rate in the study’s eight maternity hospitals. In
2005, the” ITP-two doses” coverage rate was very low in
the maternity hospitals (≤ 10%) and nil in Avamè and
Zogbo. During 2006-2007, more than half of the women
received two doses in four maternity hospitals (Guéné,
Avamè, Birni Lafia, and the hospital in the Malanville
area), then the rate evolved more quickly during the last
period (2008-2009).
In the four other maternity hospitals, progression was
slower between 2005 and 2006-2007, but it remained
constant over time to such an extent that by the end of
the study the “ITP-two doses” coverage rate at the
Malanville Health Center, for example, caught up with
the most advanced maternity hospitals at the beginning
of the study. The CNHU here again showed a specific
profile, with relatively slow but constant growth. In 2008-
2009, the “ITP-two doses” coverage rate showed high
variability between the different maternity hospitals, ran-
ging from 39% for the CNHU to 86% for Avamè.
Figure 5 shows the ITP-SP coverage rate in all the
maternity hospitals for the year 2009, the last year of
the study. The proportion of women who had received
at least one dose varied from 67% (CNHU) to 97%
(Birni Lafia), with a percentage above 80% for seven
maternity hospitals out of eight. However, the “ITP-two
doses” coverage rate was lower in all the maternity hos-
pitals, fluctuating between 45% (CNHU) and 85% (Birni
Lafia). Guéné and Birni Lafia were the two maternity
hospitals having more than 80% coverage for “ITP-two
doses.” In 2009, 87.8% of the women received at least
one dose of SP and 68.4% of them received the two
required doses. The CNHU was the center with the low-
est coverage rates.
Factors influencing administration of ITP-SP in the
maternity hospitals from 2005 to 2009
Table 1 shows the results of the final multivariate logis-
tic regression model of the variable “ITP administration”
on only the significant covariates. This analysis demon-
strates that for the entire study, beyond the period
whose very high odds-ratio reflected the rapid progres-
sion since 2005, certain factors were significantly asso-
ciated with ITP intake:
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Page 4 of 7- the geographical area (on average a better chance
of receiving ITP for pregnant women living in the
north);
- type of town (on average a better chance of receiv-
ing ITP for pregnant women living in a rural area
compared to those living in urban areas),
- the number or prenatal consultations (on average a
better chance of receiving ITP for pregnant women
who had undergone at least four prenatal
consultations).
Difficulties encountered by the staff
The main difficulty for the maternities staff is the short-
age of medicine in maternity clinics. By this way, some
women did not receive ITPp at a correct time.
Discussion
The malaria prevention strategy for pregnant women
with sulfadoxine-pyrimethamine treatment recom-
mended by the WHO in 1998 was adopted by the Beni-
nese government in 2004. However, it was only
implemented in the field starting in 2006. The present
study covered the period from 2005 to 2009, including
all the available data since the year preceding the
protocol’s implementation. The objective was to assess
t h eI T P - S Pc o v e r a g er a t ei nt w or e g i o n si nt h es o u t h
and north of the country from its implementation until
2009. The results showed that the ITP coverage rate
had evolved rapidly since implementation of the proto-
col even if this varied in the study’s eight maternity hos-
pitals. Since these were factors associated with ITP
administration, the results show that ITP administration
m a yb ea s s o c i a t e dw i t ht h et y p eo ft o w n( r u r a lo r
urban) and the geographical area (north or south), as
well as the number of prenatal consultations.
Overall, in 2005 we observed a low “ITP-at least one
dose” and “ITP-two doses” coverage rate, confirming
that in this period the administrative decision had not
been applied in the field. During this period, 92.6% of
the women in the study still received chloroquine treat-
ment. The rapid progression of the coverage rate
observed after start-up in 2006 is probably the conse-
quence of awareness campaigns and training maternity
hospital personnel in the application of this new proto-
col. This progression continued for the 2008-2009 per-
iod, although at a slower pace.
However, this overall progression hides substantial
disparity between the maternity hospitals. We noted a
globally faster progression in maternity hospitals located
in the north of Benin. A possible explanation would be
that ITP-SP may have been adopted earlier in this area
and therefore that personnel training may have taken
place earlier than in the south.
In total, in 2009, 3 years after starting up ITP-SP, all
the maternity hospitals in the north (Birni Lafia,
Guéné, Hôpital de zone, and Health Center) showed
more than 80% coverage in “ITP-at least one dose.”
Also in the south, the Tori Cada, Avamè, and Zogbo
health centers also showed a coverage rate higher than
80%. Only the CNHU was below this percentage, with
a 67% “ITP-at least one dose” coverage rate. The
maternity hospitals in the south, except for CNHU,
were no longer behind those in the north, as observed
in 2006-2007.
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Figure 5 ITP coverage rate in all the maternity hospitals in
2009.
Table 1 Significant factors in ITP-SP administration for the entire study
Variables Numbers of patients Odds ratio Confidence interval P-value
Geographical area Urban 1177 <10
-4
Rural 1243 2.77 [2.20;3.48]
Geographical location North 1119 <10
-4
South 1301 0.26 [0.20;0.33]
Study period 2005 406 <10
-4
2006-2007 974 59.46 [34.22;103.30]
2008-2009 1040 257.73 [145.22;457.41]
ANC < 4 675 <10
-4
≥ 4 1745 1.85 [1.46;2.33]
NB: ANC = Antenatal care
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Page 5 of 7However, in 2009, only two maternity hospitals out of
eight reached the 80% “ITP-two doses” coverage thresh-
old, as established as the objectives of the WHO Roll
Back Malaria [23] program and Benin’s PNLP [24] for
2010. The coverage rate varied from 45% at the CNHU
to 85% at Birni Lafia in 2009. Overall, the coverage rate
was 68% in 2009.
The difference between the number of women receiv-
ing at least one dose and those having received two
does of SP could be explained by several factors:
- too few consultations or consultations too far
apart, precluding SP administration (which cannot
be administered after the 36
th week of amenorrhea);
- a stock shortage of the drug in certain maternity
hospitals;
- late consultations for certain pregnant women (the
first prenatal consultation occurred after 32 weeks
for 5% of women), thus leaving insufficient time for
the second administration before giving birth;
- abortions or premature births occurring before the
second administration;
This study also showed that the CNHU was the center
where coverage ("ITP-two doses” and “ITP-at least one
dose”) was the lowest. Various factors can explain this:
- First, the CNHU receives a large number of preg-
nant women and may have been hit more severely
by the stock shortage of SP than expected. In this
case, it was observed that women sometimes
received another antimalarial such as chloroquine,
proguanil or the association of the two antimalarials,
for example. This may protect the pregnant woman
but does not match the national or WHO
recommendations;
- A greater proportion of women consulting at the
CNHU have an at-risk pregnancy than in the other
health centers. This is the case, for example of sulfa-
mide allergies and HIV seropositivity for which a dif-
ferent protocol is recommended [20].
Comparable studies have been conducted in Benin
and in other African countries.
- In Benin, the PNLP evaluated the strategies of
malaria control during pregnancy was conducted in
2007, in a transversal study throughout the coun-
try. It showed that 60.7% of the women surveyed in
healthcare training and 66.6% of the women in the
general population had received ITP-SP appropri-
ately (two doses), for a total of 63.7% [19]. This
percentage is close to that found in the present
study for the overall population of pregnant
women: 59.0% in 2007. This study also reported
that the availability of SP is unstable in the univer-
sity-affiliated hospitals and the departmental hospi-
tals [19]. However, it should be noted that the ITP
coverage rate was calculated based on data col-
lected on the maternal cards in our study, whereas
it was based on interviews with women in the
PNLP study.
- Several studies, in the Gambia in 2008 [25], two
others in Kenya in 2004 [26] and 2008 [27], and in
Malawi in 2000 [28], showed less rapid progression
of the ITP-two dose coverage rate than in the pre-
sent study.
- The authors suggest that these results may be
related to poor awareness on the part of women,
most of whom seemed not to return for the follow-
up doses, or problems of geographic accessibility of
the center, or socioeconomic problems [27].
The differences between these studies and ours could
also be related to the methods used. First of all, the
study periods were different, and for the studies con-
ducted in Kenya and Malawi, the data were obtained
from interviews of pregnant women, certain of whom
could have forgotten that they had received ITP-SP,
resulting in an underestimation of ITP coverage. In
addition, in Benin, where the coverage rate seems better
than that found in other studies, SP is subsidized and
distributed free.
Another factor is that in the present study the cover-
age rate reflects women who came for prenatal consulta-
tions and does not take into account women who were
not seen in these visits. In 2008 for example, the cover-
age rate in prenatal consultations was estimated at
76.9% for the Alibori department in the northern area
and 89.2% for the Atlantique department where the
Tori Cada and Tori Avamè maternity hospitals are
located. Our protocol therefore overestimates the real
ITP coverage rate to a certain extent.
Except for the study period, the geographical area
(with a higher probability of receiving ITP in the north
than in the south), and the type of town (with a higher
probability of receiving ITP in rural areas than in
towns), the results of this study show that women who
had had at least four prenatal consultations had a better
chance of receiving ITP than the others. This result
confirms the WHO recommendations [7] and the
PNLP’s recommendations as well [20], according to
which pregnant women should have at least four prena-
tal consultations, three of which after active fetal move-
ments (or after the 16
th week of amenorrhea). If SP was
administered during these last three prenatal visits, a
large proportion of pregnant women would receive the
two recommended doses.
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All in all, the administration of ITP-SP for malaria has
clearly advanced in the maternity hospitals investigated in
this study, even if the study was based only on women
who attended prenatal consultations during their preg-
nancy. A certain variability exists between the north and
the south, between rural and urban areas, and even
between the different maternity hospitals in the same
town. The availability of this drug is certainly acceptable
in some centers. If the number of women received in pre-
natal consultations remains far from the expected number
of women, the coverage rates should be even less than
what was found. This study in the two regions where
maternity hospitals were selected cannot be representative
of all of Benin, but it provides a first evaluation of how the
ITP-SP situation is evolving. This observation implies sig-
nificant actions to intensify the administration of SP as the
preventive treatment for malaria in pregnant women.
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